Loading clinical trials...
Loading clinical trials...
Phase I/II Trial of Ibrutinib, Dexamethasone, and Lenalidomide as Initial Therapy for Transplant Ineligible Multiple Myeloma Patients
Conditions
Interventions
Dexamethasone
Ibrutinib
+4 more
Locations
1
United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Start Date
March 10, 2017
Primary Completion Date
October 18, 2022
Completion Date
October 18, 2022
Last Updated
August 17, 2025
NCT05312255
NCT04508790
NCT04640779
NCT04850599
NCT04756401
NCT05288062
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions